Pharvaris N.V. (NASDAQ:PHVS - Get Free Report) has been assigned a consensus recommendation of "Buy" from the five ratings firms that are covering the company, Marketbeat Ratings reports. Five investment analysts have rated the stock with a buy rating. The average twelve-month price objective among analysts that have issued ratings on the stock in the last year is $36.20.
PHVS has been the topic of a number of analyst reports. Cantor Fitzgerald dropped their price target on Pharvaris from $28.00 to $25.00 and set an "overweight" rating on the stock in a research note on Wednesday, May 14th. Guggenheim assumed coverage on Pharvaris in a research note on Wednesday, June 11th. They set a "buy" rating and a $32.00 target price on the stock. Finally, Wedbush reaffirmed an "outperform" rating and set a $27.00 target price on shares of Pharvaris in a research note on Thursday, June 5th.
View Our Latest Stock Report on PHVS
Institutional Investors Weigh In On Pharvaris
Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its holdings in Pharvaris by 30.3% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 63,734 shares of the company's stock worth $1,222,000 after purchasing an additional 14,838 shares during the last quarter. Deutsche Bank AG lifted its holdings in Pharvaris by 13.0% in the 4th quarter. Deutsche Bank AG now owns 18,168 shares of the company's stock worth $348,000 after purchasing an additional 2,087 shares during the last quarter. Bank of America Corp DE lifted its holdings in Pharvaris by 205,286.7% in the 4th quarter. Bank of America Corp DE now owns 30,808 shares of the company's stock worth $591,000 after purchasing an additional 30,793 shares during the last quarter. JPMorgan Chase & Co. lifted its position in shares of Pharvaris by 1,125.3% during the 4th quarter. JPMorgan Chase & Co. now owns 3,100 shares of the company's stock worth $59,000 after purchasing an additional 2,847 shares during the last quarter. Finally, Legal & General Group Plc lifted its position in shares of Pharvaris by 11.2% during the 4th quarter. Legal & General Group Plc now owns 9,855 shares of the company's stock worth $189,000 after purchasing an additional 994 shares during the last quarter.
Pharvaris Stock Up 0.6%
Pharvaris stock traded up $0.12 during midday trading on Thursday, hitting $20.00. The company's stock had a trading volume of 145,311 shares, compared to its average volume of 198,380. The stock's 50-day moving average price is $18.74 and its 200-day moving average price is $17.04. Pharvaris has a 12 month low of $11.51 and a 12 month high of $26.33. The company has a market capitalization of $1.05 billion, a PE ratio of -6.64 and a beta of -2.81.
Pharvaris (NASDAQ:PHVS - Get Free Report) last issued its quarterly earnings results on Tuesday, May 13th. The company reported ($0.89) EPS for the quarter, missing the consensus estimate of ($0.80) by ($0.09). As a group, equities analysts anticipate that Pharvaris will post -2.71 EPS for the current year.
Pharvaris Company Profile
(
Get Free ReportPharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial.
Read More
Before you consider Pharvaris, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pharvaris wasn't on the list.
While Pharvaris currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
We are about to experience the greatest A.I. boom in stock market history...
Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.
That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.
- The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
- The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
- Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.
Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.
And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...
Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
MarketBeat All Access